Telix Pharmaceuticals (NASDAQ:TLX) Upgraded at Wall Street Zen

Key Points

• Wall Street Zen upgraded Telix Pharmaceuticals from a "sell" to a "hold," while analyst coverage overall is mixed (one Strong Buy, six Buy, one Hold, one Sell) leaving an average rating of "Moderate Buy" and an average target price of $21.13.
• Shares opened at $7.52 and trade near their 50-day moving average (~$7.30) but below the 200-day average ($8.96), with a 1‑year range of $6.28 to $20.00—well under the consensus target.
• Telix reported an EPS miss (($0.01) vs. $0.05 expected) and revenue of $414.02M (vs. $421.50M est.), while several institutional investors, notably Lazard Asset Management, materially increased or initiated positions in the stock.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts have also issued reports on TLX. Citigroup increased their target price on shares of Telix Pharmaceuticals from $22.00 to $22.50 and gave the stock a "buy" rating in a report on Tuesday, February 24th. HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Telix Pharmaceuticals in a research note on Wednesday, January 21st. Royal Bank Of Canada raised Telix Pharmaceuticals from a "hold" rating to a "moderate buy" rating in a research report on Monday, January 19th. Finally, Weiss Ratings reiterated a "sell (d)" rating on shares of Telix Pharmaceuticals in a report on Wednesday, January 21st. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $21.13.

Telix Pharmaceuticals Price Performance

Shares of NASDAQ:TLX opened at $7.52 on Friday. Telix Pharmaceuticals has a 1 year low of $6.28 and a 1 year high of $20.00. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The firm's 50-day moving average is $7.30 and its two-hundred day moving average is $8.96.

Telix Pharmaceuticals (NASDAQ:TLX - Get Free Report) last posted its quarterly earnings data on Thursday, February 19th. The company reported ($0.01) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.06). The firm had revenue of $414.02 million for the quarter, compared to analyst estimates of $421.50 million. Analysts anticipate that Telix Pharmaceuticals will post 0.24 EPS for the current year.

Hedge Funds Weigh In On Telix Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the company. Vident Advisory LLC acquired a new stake in Telix Pharmaceuticals in the fourth quarter valued at $204,000. XTX Topco Ltd purchased a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at about $89,000. Quadrature Capital Ltd purchased a new position in shares of Telix Pharmaceuticals in the 4th quarter valued at about $276,000. OLD Mission Capital LLC acquired a new stake in shares of Telix Pharmaceuticals during the 4th quarter worth about $111,000. Finally, Lazard Asset Management LLC raised its position in shares of Telix Pharmaceuticals by 118.6% during the 4th quarter. Lazard Asset Management LLC now owns 250,517 shares of the company's stock worth $1,876,000 after acquiring an additional 135,893 shares in the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals NASDAQ: TLX is a clinical-stage biopharmaceutical company focused on the development and commercialization of molecularly targeted radiopharmaceuticals for the diagnosis and treatment of cancer. Leveraging expertise in radiochemistry, nuclear medicine and oncology, Telix aims to address unmet clinical needs across a range of tumor types by pairing diagnostic imaging agents with therapeutic radionuclides.

The company’s pipeline spans both imaging and therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.